Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.52 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.45 |
| ▸ | CFD | P00746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712567 | 0.93 | MCHR1 (0.55) | MCHR1MAPK14CHRM4EPHX2NAMPT | |
| SCHEMBL708521 | 0.92 | MCHR1 (0.58) | MCHR1ROCK2ROCK1MAPK14CHRM4 | |
| SCHEMBL3777504 | 0.85 | MCHR1 (0.56) | MCHR1CHRM4TEAD1SCN9A | |
| SCHEMBL710203 | 0.84 | MEN1 (0.50) | MCHR1MAPK14CHRM4EPHX2NAMPT | |
| SCHEMBL5515774 | 0.83 | CARM1 (0.50) | MCHR1ROCK2ROCK1MAPK14CHRM4 | |
| SCHEMBL708602 | 0.81 | CARM1 (0.45) | MCHR1ROCK2ROCK1MAPK14CHRM4 | |
| SCHEMBL712109 | 0.81 | MCHR1 (0.57) | MCHR1CHRM4TEAD1SCN9A | |
| SCHEMBL5517975 | 0.78 | CARM1 (0.47) | MCHR1ROCK2ROCK1MAPK14EPHX2 | |
| SCHEMBL31717455 | 0.76 | MCHR1 (0.48) | MCHR1EPHX2CHRM2 | |
| SCHEMBL31717583 | 0.76 | MCHR1 (0.48) | MCHR1EPHX2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | claimed |
| EP-1869019-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | Pfizer Products Incorporated (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006106425-A1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PRODUCTS INC. (US) | 2006-10-12 | — | — | WO | claimed |
| EP-1869019-B1 | BICYCLIC [3.1.0] HETEROARYL AMIDES AS TYPE I GLYCINE TRANSPORT INHIBITORS | PFIZER PROD INC (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8124639-B2 | Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | PFIZER INC. | 2010-12-23 | — | — | US | disclosed |
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | PFIZER INC. | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324020-A1 | Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors | SLC1A2, SLC1A1, SLC6A5 | MCHR1 918/4885ROCK2 3564/4885ROCK1 2222/4885 |
| US-20060229455-A1 | Bicyclic [3.1.0.] heteroaryl amides as type 1 glycine transport inhibitors | SLC1A2, SLC1A1, GLRA1 | MCHR1 963/4885ROCK2 3765/4885ROCK1 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.